Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.
Mascarenhas J, Komrokji RS, Palandri F, Martino B, Niederwieser D, Reiter A, Scott BL, Baer MR, Hoffman R, Odenike O, Vannucchi AM, Bussolari J, Zhu E, Rose E, Sherman L, Dougherty S, Sun L, Huang F, Wan Y, Feller FM, Rizo A, Kiladjian JJ. Mascarenhas J, et al. J Clin Oncol. 2021 Sep 10;39(26):2881-2892. doi: 10.1200/JCO.20.02864. Epub 2021 Jun 17. J Clin Oncol. 2021. PMID: 34138638 Clinical Trial.
Spleen response ( 35% spleen volume reduction) and symptom response ( 50% reduction in total symptom score) rates at week 24 were coprimary end points. Secondary end points included OS and safety. ...
Spleen response ( 35% spleen volume reduction) and symptom response ( 50% reduction in total symptom score) rates at week 24 were cop …
Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
Kuykendall AT, Sun L, Mascarenhas J, Kiladjian JJ, Vannucchi AM, Wang J, Xia Q, Zhu E, Feller F, Rizo A, Bussolari J, Wan Y, Komrokji R. Kuykendall AT, et al. Ann Hematol. 2022 Jan;101(1):139-146. doi: 10.1007/s00277-021-04683-w. Epub 2021 Oct 8. Ann Hematol. 2022. PMID: 34622316 Clinical Trial.
Overall survival was measured from time of JAK inhibitor discontinuation to death or censored at last follow-up. To improve comparability, propensity score weighting approaches using average treatment effect for overlap population (ATO) and stabilized inverse probability t …
Overall survival was measured from time of JAK inhibitor discontinuation to death or censored at last follow-up. To improve comparability, p …